AstraZeneca’s pivot point might not come until 2018

Much will depend on drug trial data readouts in the second half of this year

via Construction http://ift.tt/2p8YAaj

Advertisements
This entry was published on May 2, 2017 at 4:10 pm and is filed under Main. Bookmark the permalink. Follow any comments here with the RSS feed for this post.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: